Filana Therapeutics, Inc. has announced the appointment of Jill M. Quigley to its Board of Directors, effective November 8, 2026. This strategic move is aimed at strengthening the company's leadership as it continues to develop therapies for Tuberous Sclerosis Complex (TSC)-related epilepsy. Quigley brings a wealth of experience in the biopharmaceutical industry, having previously guided companies through critical stages of drug development and financing.
Claude Nicaise, Chairman of the Board, expressed enthusiasm about Quigley's appointment, stating, "Her record of guiding companies through financings and strategic growth will broaden the expertise around our Board table." This reflects Filana's commitment to aligning its Board with the evolving needs of the company as it moves forward with its clinical programs.
Rick Barry, President and CEO of Filana Therapeutics, noted that Quigley joins the company at a pivotal moment, as it prepares for its planned Phase 2a clinical study of simufilam in TSC-related epilepsy. Patient screening is expected to begin in the first quarter of 2027. Barry emphasized the scientific rationale behind the program and expressed eagerness to collaborate with Quigley to create value for patients and shareholders.
Quigley, who is currently the CEO of a preclinical biotechnology company, has over 20 years of experience in biotechnology leadership. Her background includes executive management, corporate operations, legal affairs, and financing. She has worked with both public and private biotechnology firms, helping to establish operations and lead significant financing rounds.
In her own words, Quigley stated, "I am pleased to join the Filana Therapeutics Board and eager to contribute my experience as the Company advances simufilam through clinical development. I have been particularly impressed by Filana's commitment to patients and its science-driven approach to developing a potential new treatment for TSC-related epilepsy."
This appointment is expected to have a positive impact on Filana Therapeutics as it navigates the complexities of clinical development and seeks to deliver innovative therapies to patients. The company is listed on the Nasdaq under the ticker symbol FLNA and is classified under the Pharmaceutical Preparations sector (SIC 2834).
As Filana Therapeutics continues to make strides in its clinical programs, the industry will be watching closely to see how Quigley's experience and insights will contribute to the company's future successes.
Read Next
Manthripragada Vijay Acquires Additional Shares in Onterris
Laws James Acquires Shares in Onterris, Inc. via RSUs
Eightco Holdings CEO Acquires 100,000 Shares of Stock
Eightco CFO Vroman Acquires 15,000 Shares in Stock Transaction
Orchestra BioMed CFO Acquires Shares in Recent Filing
Upwork CFO Erica Gessert Reports Major Stock Transactions




